Daily Pill Shows Promise in Slowing Type 1 Diabetes

A 2-year follow-up of the randomized, placebo-controlled BANDIT trial reveals that stopping baricitinib results in a lack of therapeutic profit, supporting its analysis in earlier levels of kind 1 diabetes to find out whether or not it could stop or delay medical onset. In 2023, researchers in Australia launched the pioneering BANDIT (Baricitinib in New Onset Sort 1 […]



Source link